T3 Pharmaceuticals

The vision of T3 Pharmaceuticals is to improve the lives of cancer patients with highly innovative treatments. Despite significant advances of classical therapies, there remains a high need for novel and innovative medicines to treat cancer. T3 Pharmaceuticals is dedicated to filling this gap by developing highly specific and efficient treatments using live bacteria.

Visit the Main Campus

Read their success story

Success Story

Where next-gen biotech scales: T3 Pharma’s microcosm from startup to global impact

In this interview with Dr. Simon Ittig, CEO of T3 Pharma, we explore how they moved from academia to entrepreneurship, scaled within Basel’s vibrant biotech hub, and became part of Boehringer Ingelheim’s CHF 450 million acquisition, all while shaping the next generation of cancer care.

View all residents